v3.26.3
Segment Reporting - Disclosure of Operating Segment Information (Detail) - AUD ($)
 12 Months Ended
Jun. 30, 2026
Jun. 30, 2025
Jun. 30, 2024
Revenue      
License revenue $ 14,556,923 $ 0 $ 0
Other income      
Research material sales 38,607 59,709 119,089
Grant income 5,338,572 4,974,823 3,722,788
Miscellaneous income 0 390  
Net gain on foreign exchange 1,229,851 0 113,458
Interest income 3,005,047 5,287,209 3,882,757
Total revenue and other income 24,169,000 10,331,373 7,838,092
Net change on fair value movement (1,868,101) 9,242 0
Segment Result (79,304,563) (61,434,165) (42,716,625)
Profit/(loss) before income tax expense (79,304,563) (61,434,165) (42,716,625)
Income tax expense 0 0 0
Loss after income tax expense (79,304,563) (61,434,165) (42,716,625)
Total segment assets 83,267,229 156,983,434 201,579,281
Total segment liabilities 21,734,183 13,348,071 12,057,539
Immunotherapy [Member]      
Revenue      
License revenue 14,556,923 0 0
Other income      
Research material sales 38,607 59,709 119,089
Grant income 5,338,572 4,974,823 3,722,788
Total revenue and other income 19,934,102 5,034,532 3,841,877
Segment Result (81,592,146) (65,020,504) (46,556,929)
Profit/(loss) before income tax expense (81,592,146) (65,020,504) (46,556,929)
Income tax expense 0 0  
Total segment assets 83,267,229 156,983,434 201,579,281
Total segment liabilities 21,734,183 13,348,071 12,057,539
Unallocated [member]      
Revenue      
License revenue 0 0  
Other income      
Miscellaneous income 0 390  
Net gain on foreign exchange 1,229,851   113,458
Interest income 3,005,047 5,287,209 3,882,757
Total revenue and other income 4,234,898 5,296,841 3,996,215
Net change on fair value movement   9,242  
Segment Result 2,287,583 3,586,339 3,840,304
Profit/(loss) before income tax expense 2,287,583 3,586,339 $ 3,840,304
Income tax expense $ 0 $ 0